Pfizer Secures $10 Billion Acquisition of Metsera Amidst Competitive Bidding

Post by : Bianca Suleiman

Pfizer has successfully finalized a $10 billion acquisition of Metsera, a developer of obesity medications, concluding an intense bidding contest with Novo Nordisk that has captivated the pharmaceutical sector this week.

The New York-based company will offer $86.25 per share, comprising $65.60 in upfront cash and an additional contingent value right valuing up to $20.65 per share based on future achievements. This bid reflects a 3.69% premium over Metsera’s closing share price from the previous Friday.

This pivotal acquisition represents a significant strategic advancement for Pfizer, which has been eager to penetrate the rapidly expanding weight-loss drug market long dominated by competitors such as Novo Nordisk and Eli Lilly. Pfizer's prior attempts to create effective obesity treatments had not succeeded, positioning Metsera’s promising drug pipeline as an attractive acquisition target.

Among Metsera’s leading experimental drugs are MET-097i, a GLP-1 injectable, and MET-233i, an amylin-mimicking agent—both projected to collectively achieve peak sales nearing $5 billion, according to forecasts from analysts. These drugs aim at metabolic pathways akin to those that have propelled the success of Wegovy and Mounjaro, renowned offerings from Novo and Lilly.

In a last-ditch effort, Novo Nordisk made a counteroffer to reclaim its standing in the obesity market. However, it fell short as Metsera’s board deemed Novo’s proposal fraught with “unacceptably high legal and regulatory risks,” opting for Pfizer’s more straightforward cash arrangement.

The stakes in this acquisition soared from Pfizer’s initial $7.3 billion proposal last September and illustrate the escalating competition for cutting-edge obesity treatments. With the deal reaching completion, Pfizer is placing a significant bet on Metsera’s scientific advancements to re-establish a footing in one of the pharmaceutical industry’s most lucrative sectors—projected to surpass $100 billion globally by the decade's end.

Though Metsera remains unprofitable while its drugs are still undergoing development, Pfizer’s robust financial resources and extensive global presence might accelerate the path to approval and commercialization. The acquisition now awaits approval from Metsera’s shareholders, marking a potential hallmark in biotech acquisitions for the year.